AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
Log in

CVE:GAPPharmaGap Stock Price, Forecast & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
PharmaGap Inc. (PharmaGap) is a development-stage company. The Company is principally engaged in drug development and out-licensing of drug compounds. The Company is focused on the development of novel drugs for treatment of cancer and other human disease conditions. PharmaGap's lead drug compound, GAP-107B8, is in the pre-clinical testing stage and has shown in vitro and in vivo efficacy in selected cancer types. During the year ended December 31, 2011, the Company commenced specific programs to further elucidate information regarding the pharmacokinetics and toxicity profiles of GAP-107B8. A program to develop liposomal delivery formulations of GAP-107B8 in order to optimize the delivery and safety of the drug compound was completed during 2011. The Company is developing GAP-107B8 for first clinical trials in ovarian cancer, using the intra-peritoneal route of administration.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
WebN/A
Phone+1-613-2873118

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive GAP News and Ratings via Email

Sign-up to receive the latest news and ratings for GAP and its competitors with MarketBeat's FREE daily newsletter.

PharmaGap (CVE:GAP) Frequently Asked Questions

Has PharmaGap been receiving favorable news coverage?

Headlines about GAP stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. PharmaGap earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutPharmaGap.

What is PharmaGap's stock symbol?

PharmaGap trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GAP."

How do I buy shares of PharmaGap?

Shares of GAP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

How can I contact PharmaGap?

PharmaGap's mailing address is 1000 Innovation Drive, Suite 400, OTTAWA, ON K2K 2K7, Canada. The company can be reached via phone at +1-613-2873118.

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.